Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

February 28, 2011

Study Completion Date

June 30, 2011

Conditions
Hepatitis C
Interventions
DRUG

Silibinin

"comparison of different dosing schedule of Silibinin infusions (20 mg/kg/d infused over 2 hours) A: 3x5days B: 14 days C: 21 days D: 28 days~sequential the infusion duration will be shortened - 2 hours, then 1 hr and then 1/2 hr/infusion"

DRUG

Silibinin

20 mg/kg Silibinin iv /d /21 days, antiviral combination therapy will be continued

Trial Locations (1)

A1090

Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT00684268 - Intravenous Silibinin in Combination With Peg-interferon and Ribavirin in Nonresponders | Biotech Hunter | Biotech Hunter